ClinicalTrials.gg
RecruitingNCT06812533Updated Oct 6, 2026

Alleviant ALLAY-HFrEF Study

An interventional study of Alleviant ALV1 System and Sham-Control in Heart Failure, sponsored by Alleviant Medical, Inc.. Recruiting at 70 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Alleviant Medical, Inc. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Oct 6, 2026First site in SerbiaSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,157 studies in Heart Failure with a site in United States — 347 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
325th of 1,601
350 · median 65
Started
2025
with 107 others
No phase
886 of 2,157
159 open now
Primary completion
2028-12
later than 342 of 436 live
Registered
1,982nd of 2,157
by date

Among the 2,157 studies in Heart Failure with a site in United States, this one is the 325th largest by planned enrollment of the 1,601 interventional ones that give a count, is one of 108 that started in 2025, is one of 886 with no phase, reaches primary completion later than 342 of the 436 other live ones, and was the 1,982nd registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

347 of the 2,157 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,157 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≤ 40%
  • class II, III or ambulatory IV HF
  • Receiving optimal, maximally tolerated, stable GDMT

Exclusion criteria

Exclusion Criteria:

  • Advanced heart failure
  • Life-expectancy \< 12 months
  • Evidence of right heart dysfunction
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    Treatment

    Subjects randomized to the treatment arm will undergo cardiac imaging, femoral vein access and receive the Alleviant ALV1 System device procedure.

    Device: Alleviant ALV1 System

  • Sham comparator
    Control

    Subjects randomized to the control arm will undergo cardiac imaging and sheath placement in femoral vein.

    Other: Sham-Control

Interventions

  • DeviceAlleviant ALV1 System

    Creation of interatrial shunt

  • OtherSham-Control

    Cardiac imaging

06

What researchers measure

Primary outcomes

  1. Composite Primary Endpoint

    The primary endpoint is a composite of all-cause mortality or cardiac transplantation or permanent left ventricular assist device (LVAD) and heart failure events.

    Time frame: 12-Month

07

Study locations

68 of 70 sites recruiting
  • Keck Medical Center of USC
    Los Angeles, California 90033, United States
    Recruiting
    • Michael Fong, MD · Principal investigator
  • University California Los Angeles Medical Center
    Los Angeles, California 90095, United States
    Recruiting
    • Richard Cheng, MD · Principal investigator
  • UC Davis Medical Center
    Sacramento, California 95817, United States
    Recruiting
    • Tai Pham, MD · Principal investigator
  • Scripps Clinical Research Services
    San Diego, California 92121, United States
    Recruiting
    • Rajeev Mohan, MD · Principal investigator
  • University of California San Francisco
    San Francisco, California 94143, United States
    Recruiting
    • Liviu Klein, MD · Principal investigator
  • Delray Medical Center
    Delray Beach, Florida 33484, United States
    Recruiting
    • Philip Habib, MD · Principal investigator
  • Ascension Sacred Heart
    Pensacola, Florida 32504, United States
    Recruiting
    • Rohit Amin, MD · Principal investigator
  • Tampa General Hospital
    Tampa, Florida 33606, United States
    Recruiting
    • Jason Feliberti, MD · Principal investigator
  • Atlanta VA Health Care System
    Decatur, Georgia 30032, United States
    Recruiting
    • Gautum Kumar, MD · Principal investigator
  • Midwest Cardiovascular Institute
    Naperville, Illinois 60540, United States
    Recruiting
    • Stanislaw Skaluba, MD · Principal investigator
  • Cardiovascular Institute of the South
    Houma, Louisiana 70360, United States
    Recruiting
    • Peter Fail, MD · Principal investigator
  • University Medical Center New Orleans
    New Orleans, Louisiana 70112, United States
    Recruiting
    • Frank Smart, MD · Principal investigator
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
    Recruiting
    • Jeong Hwan Kim, MD · Principal investigator
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • Pinak Shah, MD · Principal investigator
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
    Recruiting
    • Nir Ayalon, MD · Principal investigator
  • Minneapolis Heart Institute Foundation
    Minneapolis, Minnesota 55407, United States
    Recruiting
    • Peter Eckman, MD · Principal investigator
  • Washington University - St Louis
    St Louis, Missouri 63110, United States
    Recruiting
    • Ali Javaheri, MD, PhD · Principal investigator
  • UMC of Southern Nevada
    Las Vegas, Nevada 89102, United States
    Recruiting
    • Ahsan Chowdhury · Principal investigator
  • Deborah Heart & Lung Center
    Browns Mills, New Jersey 08015, United States
    Recruiting
    • Geurys Rojas-Marte · Principal investigator
  • Englewood Medical Center
    Englewood, New Jersey 07631, United States
    Recruiting
    • Ramin Hastings · Principal investigator
  • Stony Brook Medicine
    New York, New York 11794, United States
    Recruiting
    • Ahmad Alkhalil, MD · Principal investigator
  • Rochester General Hospital
    Rochester, New York 14621, United States
    Recruiting
    • Elizabeth Lee, MD · Principal investigator
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
    Recruiting
    • Denizhan Ozdemir, MD, PhD · Principal investigator
  • Mission Hospital
    Asheville, North Carolina 28801, United States
    Recruiting
    • Vinay Thohan, MD · Principal investigator
  • Duke University Hospital
    Durham, North Carolina 27705, United States
    Recruiting
    • Robert Mentz, MD, FACC, FAHA, HFSA · Principal investigator
  • NC Heart and Vascular Research
    Raleigh, North Carolina 27607, United States
    Recruiting
    • Elizabeth Volz, MD · Principal investigator
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • J. Emanuel Finet, MD · Principal investigator
  • ProMedica Toledo Hospital
    Toledo, Ohio 43606, United States
    Recruiting
    • P. Kasi Ramanathan, MD · Principal investigator
  • Pinnacle Health Cardiovascular Institute
    Harrisburg, Pennsylvania 17101, United States
    Recruiting
    • Hemal Gada, MD · Principal investigator
  • Roper St. Francis Healthcare
    Charleston, South Carolina 29414, United States
    Recruiting
    • Matthew O'Steen, MD · Principal investigator
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
    • Brian Houston, MD · Principal investigator
  • Monument Health
    Rapid City, South Dakota 57701, United States
    Recruiting
    • Luis Hernandez, MD · Principal investigator
  • Tennova Healthcare - Turkey Creek Medical Center
    Knoxville, Tennessee 37934, United States
    Recruiting
    • Malcolm Foster · Principal investigator
  • Hendrick Health
    Abilene, Texas 79601, United States
    Recruiting
    • Mark Lawrence, D.O. · Principal investigator
  • Texas Cardiac Arrhythmia Research Foundation
    Austin, Texas 78705, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Austin Heart
    Austin, Texas 78756, United States
    Recruiting
    • Kunjan Bhatt, MD · Principal investigator
  • Baylor Scott & White Research Institute
    Plano, Texas 75093, United States
    Recruiting
    • Molly Szerlip · Principal investigator
  • Baylor Scott & White - Temple
    Temple, Texas 76508, United States
    Recruiting
    • Ernesto Ruiz Duque, MD · Principal investigator
  • Waco Cardiology
    Waco, Texas 76712, United States
    Recruiting
    • Donald Cross, MD · Principal investigator
  • Carilion Clinic
    Roanoke, Virginia 24014, United States
    Recruiting
    • Daniel Pauly, MD · Principal investigator
  • Monash Health Victorian Heart Hospital
    Clayton, Victoria 3068, Australia
    Recruiting
    • Robert Gooley · Principal investigator
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
    Recruiting
    • David Kaye · Principal investigator
  • OLV Hospital
    Aalst, Belgium
    Recruiting
    • Jozef Bartunek, Prof. · Principal investigator
  • ZAS Middelheim
    Antwerp, Belgium
    Recruiting
    • Stefan Verheye · Principal investigator
  • AZ Sint Jan Brugge
    Bruges, Belgium
    Recruiting
    • Jan Van der Heyden, Prof. · Principal investigator
  • Southlake Regional Hospital Centre
    Newmarket, Ontario L3Y 2P6, Canada
    Recruiting
    • Liane Porepa, MD · Principal investigator
  • Centre hospitalier de l'Universite de Montreal (CHUM)
    Montreal, Quebec H2X 0C1, Canada
    Recruiting
    • Brian Potter, MD · Principal investigator
  • Centre Integre Universitaire de Sainte et de Services Scoiiaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS)
    Montreal, Quebec H2X 0C1, Canada
    Recruiting
    • Benoit Daneault, MD · Principal investigator
  • IUCPQ - Université Laval (Quebec)
    Québec, Quebec G1V 4G5, Canada
    Recruiting
    • Josep Rodés-Cabau, MD, PhD · Principal investigator
  • Tbilisi Heart and Vascular
    Tbilisi, Georgia
    Recruiting
    • Tamaz Shaburishvili · Principal investigator
  • Hippocration General Hospital Athens
    Athens, 11527, Greece
    Recruiting
    • Konstantinos Toutouzas · Principal investigator
  • Hygeia Hospital
    Athens, 15123, Greece
    Recruiting
    • Elias Tsougos · Principal investigator
  • European Interbalken Medical Center
    Thessaloniki, Greece
    Recruiting
    • Vlasis Ninios · Principal investigator
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, Israel
    Recruiting
    • Michael Laufer-Perl · Principal investigator
  • Shamir Medical Center
    Zrifin, Israel
    Recruiting
    • Gil Moravsky · Principal investigator
  • ChristChurch Hospital
    Christchurch, 8011, New Zealand
    Recruiting
    • Richard Troughton · Principal investigator
  • Dunedin Hospital
    Dunedin, 9016, New Zealand
    Recruiting
    • Gerard Wilkins · Principal investigator
  • University Clinical Hospital in Opole
    Opole, Poland
    Recruiting
    • Jerzy Sacha · Principal investigator
  • Narodowy Instytut Kardiologii im. Stefana kardynała Wyszyńsk
    Warsaw, Poland
    Recruiting
    • Przemysław Leszek · Principal investigator
  • Uniwesytecki Szpital Kliniczny
    Wroclaw, Poland
    Recruiting
    • Jan Biegus, Prof. · Principal investigator
  • National Institute for Heart and Blood Vessels Dedinje
    Belgrade, 11040, Serbia
    Recruiting
    • Stefan Simović · Principal investigator
  • University Clinical Centre of Kragujevac
    Kragujevac, 34000, Serbia
    Recruiting
    • Stefan Simović · Principal investigator
  • Hospital Universitario A Coruna
    A Coruña, Spain
    Recruiting
    • Maria Generosa Crespo Leiro, Prof. · Principal investigator
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08025, Spain
    Recruiting
    • Sonia Mirabet, MD, PhD · Principal investigator
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
    Recruiting
    • Omar Abdul-Jawad Altisent · Principal investigator
  • Vall d'Hebron University Hospital Barcelona
    Barcelona, Spain
    Recruiting
    • Eduardo Rodenas-Alesina · Principal investigator
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
    Terminated

    Not enrolling at this site — choose another above.

  • Hospital Universitario Puerta de Hierro
    Madrid, 28222, Spain
    Recruiting
    • Marta Cobo Marcos, Prof. · Principal investigator
  • Hospital Clínico Universitario de Salamanca
    Salamanca, Spain
    Recruiting
    • David González Calle, MD · Principal investigator
  • Valencia Hospital Clinico
    Valencia, 46010, Spain
    Recruiting
    • Julio Nunez · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2028, 45 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 62. This study's planned 45 months is above that.

Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Feb 6, 2025
StartActual
Mar 10, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 1 site removed — first site in Serbia. University of Rochester Medical Center is now Recruiting
Show 3 added (2 Serbia, 1 Canada)
  • IUCPQ - Université Laval (Quebec) · Québec, Canada
  • National Institute for Heart and Blood Vessels Dedinje · Belgrade, Serbia
  • University Clinical Centre of Kragujevac · Kragujevac, Serbia
Show 1 removed
  • IUCPQ - Université Laval (Quebec) · Québec, Canada
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    3 sites added, 1 site removed — first site in Serbia. University of Rochester Medical Center is now Recruiting
    Show 3 added (2 Serbia, 1 Canada)
    • IUCPQ - Université Laval (Quebec) · Québec, Canada
    • National Institute for Heart and Blood Vessels Dedinje · Belgrade, Serbia
    • University Clinical Centre of Kragujevac · Kragujevac, Serbia
    Show 1 removed
    • IUCPQ - Université Laval (Quebec) · Québec, Canada
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06812533
Lead sponsor
Alleviant Medical, Inc.
Responsible party
Sponsor
First posted
Feb 6, 2025
Start date
Mar 10, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Stacia Kraus
Contact
stacia.kraus@alleviantmedical.com
612-387-4552
Gregg Stone
principal investigator · Icahn School of Medicine at Mount Sinai
James Udelson
principal investigator · Tufts Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion